Ovarian Cancer Diagnostics Market By Diagnostic (Imaging Techniques {Ultrasound, CT Scan, MRI, PET Scan}, Biomarker Testing {CA-125, HE4, OVA1, ROMA}, Genetic Testing {BRCA1/BRCA2 and Others}, Biopsy, Laparoscopy, and Others), By Type (Epithelial Tumors, Germ Cell Tumors, and Stromal Tumors), By End-user (Hospitals, Clinics, Diagnostic Laboratories, and Cancer Research Institutes), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Published Date: Dec 2024 | Report ID: MI1471 | 215 Pages

Report Summary Table of Contents Segmentation FAQ Request Free Sample Report

Report Coverage:

By Diagnostic

  • Imaging Techniques
    • Ultrasound
    • CT Scan
    • MRI
    • PET Scan
  • Biomarker Testing
    • CA-125
    • HE4
    • OVA1
    • ROMA
  • Genetic Testing
    • BRCA1/BRCA2
    • Others
  • Biopsy
  • Laparoscopy
  • Others

By Type

  • Epithelial Tumors
  • Germ Cell Tumors
  • Stromal Tumors

By End-user

  • Hospitals
  • Clinics
  • Diagnostic Laboratories
  • Cancer Research Institutes

By Region

North America

  • U.S.
  • Canada

Europe

  • U.K.
  • France
  • Germany
  • Italy
  • Spain
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Singapore
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America

Middle East & Africa

  • GCC Countries
  • South Africa
  • Rest of the Middle East & Africa

List of Companies:

  • Abbott Laboratories
  • Roche Diagnostics
  • Thermo Fisher Scientific
  • BioMérieux
  • Illumina, Inc.
  • Qiagen N.V.
  • Myriad Genetics
  • Guardant Health
  • Freenome
  • Labcorp
  • Medtronic
  • Siemens Healthineers
  • Hologic, Inc.
  • Genomic Health
  • OncoOne, Inc.

Maximize your value and knowledge with our 5 Reports-in-1 Bundle - over 40% off!

Our analysts are ready to help you immediately.

Request Bundle Pricing